{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:35:15Z","timestamp":1784774115480,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The administration of anticancer drugs in females with comorbidity increases the risk for cancer therapy-related cardiovascular toxicity (CTR-CVT), which in turn contributes to cardiovascular disease (CVD). Furthermore, a pathophysiological connection between cancer and cardiovascular disease may exist.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the long-term risks and predictors of CTR-CVT, including clinical hypertension (HT), coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), as well as all-cause mortality in women diagnosed with early breast cancer (BC) and eligible for adjuvant chemotherapy in Sweden.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were extracted from Swedish registers and medical records on 433 women, 18-60 years of age, diagnosed 1998-2002 with lymph node-positive BC, and considered for adjuvant chemotherapy. CTR-CVT was defined as HT, CAD, HF, or AF after the diagnosis of BC. Follow-up was from the date of BC diagnosis until November 30, 2021, or death. Prevalence of CTR-CVT and all-cause mortality were calculated. Hazard ratios (HR) were determined for factors associated with CTR-CVT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age was 50 (interquartile range (IQR) 32) years. 910 CTR-CVT events were diagnosed in 311 women with a median of 19.3 (IQR 15,3) years follow-up. The proportions of CTR-CVT events were: HT 281 (64%); CAD 198 (46%); HF 206 (47%); and AF 225 (51%). The cumulative incidence of CTR-CVT was 71.8%, and 50% of all 433 patients developed CTR-CVT within 11.7 years of BC diagnosis (standard deviation (SD) 0.57, 95% confidence interval (CI) 10.6-12.9). Age was a risk factor for CTR-CVT. Anthracycline increased the risk for HF (p=0,001; HR 2,0; 95%CI 1,4-2,8), CAD (p= 0,002; HR 1,7; 95% CI 1,2-2,4), and AF (p=0,013; HR 1,5; 95% CI 1,0-2,0). At the end of the 24-year study period, 227 of the 433 women were alive, and the total cumulative mortality was 47,6%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The prevalence of CTR-CVT and all-cause mortality is high after BC diagnosis and treatment, particularly in older patients and those receiving anthracyclines. These findings and the onset of CTR-CVT support cardio-oncology guidelines recommending initial risk stratification and cardiovascular monitoring during treatment, followed by long-term annual screening for cardiovascular risk factors and CTR-CVT among BC survivors.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1095251","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T04:29:41Z","timestamp":1681878581000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: a Swedish cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Laila","family":"Hubbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Mallios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patric","family":"Karlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andri","family":"Papakonstantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Hedayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11912-019-0796-0","article-title":"Cardiovascular disease and cancer: is there increasing overlap","volume":"21","author":"Vincent","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.0722","article-title":"Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials","volume":"35","author":"Taylor","year":"2017","journal-title":"J Clin Oncol"},{"key":"B4","article-title":"Statistics on cancer incidence 2020","volume-title":"Socialstyrelsen, editor","year":"2020"},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomized trials","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomized trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60488-8","article-title":"Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomized trials","volume":"383","author":"Ebctcg","year":"2014","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67887-7","article-title":"Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials","volume":"366","author":"Clarke","year":"2005","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr Cardiol Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/medsci10020027","article-title":"New insights on the toxicity on heart and vessels of breast cancer therapies","volume":"10","author":"Lanza","year":"2022","journal-title":"Med Sci (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2022.01.002","article-title":"Emerging technologies in mitigating the risks of cardiac toxicity from breast radiotherapy","volume":"32","author":"Lin","year":"2022","journal-title":"Semin Radiat Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1539","article-title":"Cancer and heart disease: associations and relations","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002533","article-title":"Cancer and its association with the development of coronary artery calcification: an assessment from the multi-ethnic study of atherosclerosis","volume":"4","author":"Whitlock","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2049487","DOI":"10.1080\/2162402X.2022.2049487","article-title":"Neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress","volume":"11","author":"Cedervall","year":"2022","journal-title":"Oncoimmunology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1169176","article-title":"Corrigendum: cardio-oncology in the COVID era (Co & co): the never-ending story","volume":"10","author":"Bisceglia","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1168","article-title":"Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial","volume":"20","author":"Banke","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2020.0062","article-title":"Incidence of long-term cardiotoxicity and evolution of the systolic function in patients with breast cancer treated with anthracyclines","volume":"29","author":"Mata Caballero","year":"2022","journal-title":"Cardiol J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28683","article-title":"Improving the TNM classification: findings from a 10-year continuous literature review","volume":"135","author":"Webber","year":"2014","journal-title":"Int J Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1476-072X-10-5","article-title":"Cardiovascular disease occurrence in two close but different social environments","volume":"10","author":"Wennerholm","year":"2011","journal-title":"Int J Health Geogr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.11.040","article-title":"Cardiovascular disease risk in a Large, population-based cohort of breast cancer survivors","volume":"94","author":"Boekel","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e27917","DOI":"10.7759\/cureus.27917","article-title":"Breast cancer and the cardiovascular disease: a narrative review","volume":"14","author":"Cherukuri","year":"2022","journal-title":"Cureus"},{"key":"B23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4103\/ijmr.IJMR_879_20","article-title":"Cardiac morbidity & mortality in patients with breast cancer: a review","volume":"154","author":"Dhir","year":"2021","journal-title":"Indian J Med Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11936-014-0315-4","article-title":"Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment","volume":"16","author":"Raj","year":"2014","journal-title":"Curr Treat options Cardiovasc Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.171","article-title":"Breast cancer therapy-associated cardiovascular disease","volume":"13","author":"Zagar","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.01.009","article-title":"Improved outcome from substituting methotrexate with epirubicin: results from a randomized comparison of CMF versus CEF in patients with primary breast cancer","volume":"43","author":"Ejlertsen","year":"2007","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.06.007","article-title":"Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification","volume":"3","author":"Bergom","year":"2021","journal-title":"JACC CardioOncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000023528","article-title":"Selective oestrogen receptor modulators","author":"Burger","year":"2000","journal-title":"Horm Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2004.00412.x","article-title":"Effects of oestrogen receptor-active compounds on lipid metabolism","volume":"7","author":"Lakoski","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.8.1003","article-title":"Residual lifetime risk for developing hypertension in middle-aged women and men: the framingham heart study","volume":"287","author":"Vasan","year":"2002","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.10.043","article-title":"Lifetime risk of heart failure among participants in the framingham study","volume":"79","author":"Vasan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study","volume":"34","author":"Armenian","year":"2016","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10147-022-02276-9","article-title":"Risk of mortality and other adverse outcomes from myocardial infarction in cancer survivors: a meta-analysis","volume":"28","author":"Dongchen","year":"2023","journal-title":"Int J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2016.07.003","article-title":"Cardiotoxicity of aromatase inhibitors in breast cancer patients","volume":"17","author":"Foglietta","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026396","article-title":"On the natural history of coronary artery disease: a longitudinal nationwide serial angiography study","volume":"11","author":"Mohammad","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jccase.2019.08.005","article-title":"Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil","volume":"20","author":"Moriyama","year":"2019","journal-title":"J Cardiol Cases"},{"key":"B37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.3390\/biomedicines10092116","article-title":"Inflammatory cytokine: an attractive target for cancer treatment","volume":"10","author":"Lee","year":"2022","journal-title":"Biomedicines"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.017","article-title":"Inflammation, aging, and cardiovascular disease: JACC review topic of the week","volume":"79","author":"Liberale","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.09.018","article-title":"Interleukin-6 and c-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation","volume":"170","author":"Aulin","year":"2015","journal-title":"Am Heart J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-308887","article-title":"Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation","volume":"102","author":"Hijazi","year":"2016","journal-title":"Heart"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1095251\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T04:29:45Z","timestamp":1681878585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1095251\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":42,"alternative-id":["10.3389\/fonc.2023.1095251"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1095251","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"article-number":"1095251"}}